Is there any anecdotal evidence supporting the use of colchicine for thyroid eye disease?

No Evidence Supporting Colchicine for Thyroid Eye Disease

Based on the available evidence, colchicine is not recommended for thyroid eye disease (TED), as there is only one small, outdated study from 2006 showing potential benefit, which has not been validated or incorporated into any modern treatment guidelines.

The Single Study Available

The only evidence for colchicine in TED comes from a 2006 Brazilian prospective randomized trial 1. This study compared colchicine (1.5 mg/day) to prednisone (0.75 mg/kg/day) in 22 patients during the inflammatory phase of Graves' ophthalmopathy. The study reported:

• 68% of orbits showed improvement in clinical activity score (CAS) in both groups
• Signal intensity ratio on MRI decreased similarly in both groups (not statistically different, p=0.22)
• Colchicine had no side effects compared to multiple steroid-related adverse events

However, this single small study has critical limitations:

• Very small sample size (only 22 patients total)
• Nearly 20 years old with no subsequent validation studies
• Not mentioned in any current TED treatment guidelines
• No follow-up research to confirm or refute these findings

Current Evidence-Based Treatment Landscape

Modern TED management has evolved significantly since 2006, with no role for colchicine in contemporary guidelines 2:

First-line therapies for active moderate-to-severe TED include:

• Teprotumumab (IGF-1R inhibitor) - now FDA-approved and replacing immunosuppressive agents as first-line therapy in the United States 2
• Intravenous methylprednisolone (IVMP) according to EUGOGO protocols
• Orbital radiotherapy in selected cases

Emerging therapies under investigation:

• Tocilizumab (IL-6 inhibitor) showing promising results 3
• Other biologics targeting specific inflammatory pathways 4

Why Colchicine Is Not Used

The mechanism of colchicine involves disrupting microtubule formation and interfering with inflammasome assembly 5. While theoretically this could address some inflammatory aspects of TED, the pathophysiology of TED centers on IGF-1R activation and autoimmune inflammation that is better targeted by modern biologics 2.

Korean practice patterns (2025) and international guidelines (2022-2026) make no mention of colchicine 6, 7, despite comprehensive reviews of TED management strategies. This absence is telling - if colchicine had meaningful efficacy, it would have been incorporated into practice given its low cost and favorable side effect profile compared to steroids.

Clinical Bottom Line

Do not use colchicine for TED. The single 2006 study showing equivalence to prednisone has not been replicated, validated, or adopted into clinical practice. Current evidence-based management focuses on:

1. Active moderate-to-severe TED: Teprotumumab or IV methylprednisolone
2. Dysthyroid optic neuropathy: IV steroids ± orbital radiotherapy, with teprotumumab for refractory cases 2
3. Chronic inactive TED: Surgical rehabilitation when indicated

The treatment landscape has fundamentally shifted toward targeted biologic therapy with superior efficacy to traditional immunosuppression 2. Colchicine represents an abandoned therapeutic avenue that never gained traction beyond a single small trial.